An update to our reporting on recently-approved Alzheimer’s drugs. You may recall FDA advisers and many independent watchdogs said there’s no good evidence the hugely expensive shots make a meaningful difference, and they could cause serious side effects. But the […]
Now an important update to our coverage of a new Alzheimer’s drug that drew so much controversy. Aducanumab was approved without one yes vote from the FDA advisory committee. In fact, several members quit over it. And critics say it
An update on our coverage of the Alzheimer’s drug Aduhelm. And a resident of San Francisco’s drug-riddled Tenderloin District talks about the nightmarish turn she says the neighborhood has taken with the City’s permission.
After Hours: Alzheimer’s Drug Update & San Francisco’s Open-Air Drug Market (Podcast) Read More »
The chief executive of the drug company that created one of the most controversial drugs in the history of FDA approval is resigning, according to reports. Michael Vounatsos presided over Biogen during a rocky time during which the company halted,
CEO of company that makes miracle Alzheimer’s-drug-gone-wrong resigns Read More »
The biggest new hope for a blockbuster drug to cure Alzheimer’s has been mired in controversy ever since it went to market. Critics say it’s a sign of declining standards and conflicts of interest at the FDA. And now, the
The following is an excerpt from Medpage Today. A man treated with the recently approved Alzheimer’s drug aducanumab (Aduhelm) had six amyloid-related imaging abnormality (ARIA) episodes, researchers reported. Over 44 months in a long-term extension study, the Alzheimer’s disease patient
The Centers for Disease Control (CDC) is grappling with another public relations challenge after the disclosure that heart inflammation, known as myocarditis, has hit some teens and young people after Covid-19 vaccination. The news of potential heart-related concerns with the
(READ) CDC: Reports of heart inflammation in teens after Covid-19 vaccine Read More »
It’s estimated that about six million people in the U.S. have the dreaded form of dementia known as Alzheimer’s disease. The search for a cure has fallen frustratingly short. Now, one pharmaceutical company says a cure, at least for early
(WATCH) Is new Alzheimer’s drug effective or “futile”? Read More »
